Amneal Pharmaceuticals (AMRX) Shares Outstanding (Weighted Average) (2017 - 2026)

Amneal Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $316.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 1.6% year-over-year to $316.0 million; the TTM figure through Mar 2026 stood at $316.0 million (up 1.6% YoY), while the FY2025 annual figure was $313.4 million, up 1.42% from the prior year.
• Shares Outstanding (Weighted Average) was $316.0 million for Q1 2026 at Amneal Pharmaceuticals, up from $313.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $316.0 million in Q1 2026 to a low of $149.9 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $237.7 million across 5 years, with a median of $307.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) jumped 102.01% in 2024, then climbed 1.23% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $150.9 million in 2022, then climbed by 16.69% to $176.1 million in 2023, then surged by 75.42% to $309.0 million in 2024, then increased by 1.42% to $313.4 million in 2025, then grew by 0.85% to $316.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $316.0 million (Q1 2026), $313.4 million (Q4 2025), and $314.2 million (Q3 2025), per Business Quant data.